Haemophilus influenzae type b disease and vaccine booster dose deferral, United States, 1998-2009

Pediatrics

Volumn 130, Issue 3, 2012, Pages 414-420

  Briere, Elizabeth C ^a   Jackson, Michael ^a   Shah, Shetul G ^a,b   Cohn, Amanda C ^a   Anderson, Raydel D ^a   MacNeil, Jessica R ^a   Coronado, Fatima M ^a   Mayer, Leonard W ^a   Clark, Thomas A ^a   Messonnier, Nancy E ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b ICF INTERNATIONAL   (United States)

Author keywords

Children; Epidemiology; Haemophilus influenzae; Haemophilus influenzae type b; United States; Vaccine preventable diseases

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B VACCINE;

ARTICLE; DEMOGRAPHY; DRUG DOSE REGIMEN; GENDER; HAEMOPHILUS INFECTION; HAEMOPHILUS INFLUENZAE TYPE B DISEASE; HUMAN; MORBIDITY; PRIORITY JOURNAL; RACE; SEROTYPE; UNITED STATES; VACCINATION;

CHILD, PRESCHOOL; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS VACCINES; HUMANS; IMMUNIZATION, SECONDARY; INCIDENCE; INFANT; UNITED STATES;

EID: 84865759026     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2012-0266     Document Type: Article

References (40)

1. Wenger JD, Hightower AW, Facklam RR, Gaventa S, Broome CV; The Bacterial Meningitis Study Group. Bacterial meningitis in the United States, 1986: report of a multistate surveillance study. J Infect Dis. 1990;162(6):1316-1323
2. Bisgard KM, Kao A, Leake J, Strebel PM, Perkins BA, Wharton M. Haemophilus influenzae invasive disease in the United States, 1994-1995: near disappearance of a vaccine-preventable childhood disease. Emerg Infect Dis. 1998;4(2):229-237
3. Adams WG, Deaver KA, Cochi SL, et al. Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA. 1993;269(2):221-226
4. Centers for Disease Control and Prevention (CDC). Progress toward elimination of Haemophilus influenzae type b disease among infants and children - United States, 1987-1995. MMWR Morb Mortal Wkly Rep. 1996;45(42):901-906
5. Centers for Disease Control and Prevention (CDC). Progress toward eliminating Haemophilus influenzae type b disease among infants and children - United States, 1987-1997. MMWR Morb Mortal Wkly Rep. 1998;47(46):993-998
6. Centers for Disease Control and Prevention (CDC). Progress toward elimination of Haemophilus influenzae type b invasive disease among infants and children - United States, 1998-2000. MMWR Morb Mortal Wkly Rep. 2002;51(11):234-237
7. Centers for Disease Control and Prevention (CDC). Interim recommendations for the use of Haemophilus influenzae type b (Hib) conjugate vaccines related to the recall of certain lots of Hib-containing vaccines (PedvaxHIB and Comvax). MMWR Morb Mortal Wkly Rep. 2007;56(50):1318-1320
8. Centers for Disease Control and Prevention (CDC). Updated recommendations for use of Haemophilus influenzae type b (Hib) vaccine: reinstatement of the booster dose at ages 12-15 months. MMWR Morb Mortal Wkly Rep. 2009;58(24):673-674
9. Centers for Disease Control and Prevention (CDC). Licensure of a Haemophilus influenzae type b (Hib) vaccine (Hiberix) and updated recommendations for use of Hib vaccine. MMWR Morb Mortal Wkly Rep. 2009;58(36):1008-1009
10. Centers for Disease Control and Prevention. Immunization Works! February 2010 Issue. 2010. Available at: www.cdc.gov/vaccines/news/newsltrs/imwrks/2010/ 201002.htm. Accessed July 18, 2011
11. Food and Drug Administration. Biologic Product Shortages. 2011. Available at: www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/Shortages/default. htm. Accessed July 18, 2011
12. Centers for Disease Control and Prevention. National Noti fiable Diseases Surveillance System. Available at: www.cdc.gov/osels/ph-surveillance/nndss/ nndsshis.htm. Accessed November 14, 2011
13. Centers for Disease Control and Prevention. National Electronic Telecommunications System for Surveillance. Available at: www.cdc.gov/osels/ph- surveillance/nndss/netss.htm. Accessed November 14, 2011
14. Centers for Disease Control and Prevention. Active Bacterial Core surveillance (ABCs). Available at: www.cdc.gov/abcs/overview/index.html. Accessed January 12, 2011
15. Schuchat A, Hilger T, Zell E, et al Active Bacterial Core Surveillance Team of the Emerging Infections Program Network. Active bacterial core surveillance of the emerging infections program network. Emerg Infect Dis. 2001;7(1):92-99
16. Wang X, Mair R, Hatcher C, et al. Detection of bacterial pathogens in Mongolia meningitis surveillance with a new real-time PCR assay to detect Haemophilus influenzae. Int J Med Microbiol. 2011;301(4):303-309
17. Pittman M. Variation and type specificity in the bacterial species Hemophilus influenza. J Exp Med. 1931;53(4):471-492
18. World Health Organization. Laboratory Methods for the Diagnosis of Meningitis Caused by Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenza. 2nd ed. Geneva, Switzerland: World Health Organization; 2011
19. CDC Wonder: Census Population Information. Available at: http://wonder.cdc.gov/population.html. Accessed August 10, 2010
20. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4(2):213-226
21. Centers for Disease Control and Prevention (CDC). Invasive Haemophilus influenzae Type B disease in five young children - Minnesota, 2008. MMWR Morb Mortal Wkly Rep. 2009;58(3):58-60
22. Ladhani S, Slack MP, Heys M, White J, Ramsay ME. Fall in Haemophilus influenzae serotype b (Hib) disease following implementation of a booster campaign. Arch Dis Child. 2008;93(8):665-669
23. Trotter CL, Ramsay ME, Slack MP. Rising incidence of Haemophilus influenzae type b disease in England and Wales indicates a need for a second catch-up vaccination campaign. Commun Dis Public Health. 2003;6(1):55-58
24. Jackson ML, Rose CE, Cohn A, et al. Modeling insights into Haemophilus influenzae type b disease, transmission, and vaccine programs. Emerg Infect Dis. 2012;18(1):13-20
25. Centers for Disease Control and Prevention (CDC). Changes in measurement of Haemophilus influenzae serotype b (Hib) vaccination coverage - National Immunization Survey, United States, 2009. MMWR Morb Mortal Wkly Rep. 2010;59(33):1069-1072
26. Centers for Disease Control and Prevention (CDC). Estimated vaccination coverage with individual vaccines and selected vaccination series among children 19-35 months of age by state and local area, July 2006-June 2007. Available at: www.cdc.gov/vaccines/stats-surv/nis/data/tables-0607.htm. Accessed November 24, 2010
27. Mohle-Boetani JC, Ajello G, Breneman E, et al. Carriage of Haemophilus influenzae type b in children after widespread vaccination with conjugate Haemophilus influenzae type b vaccines. Pediatr Infect Dis J. 1993;12(7):589-593
28. Takala AK, Eskola J, Leinonen M, et al. Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugate vaccine. J Infect Dis. 1991;164(5):982-986
29. Barbour ML. Conjugate vaccines and the carriage of Haemophilus influenzae type b. Emerg Infect Dis. 1996;2(3):176-182
30. Santibanez TA, Shefer A, Briere EC, Cohn AC, Groom AV. Effects of a nationwide Hib vaccine shortage on vaccination coverage in the United States. Vaccine. 2012;30(5):941-947
31. Lowther SA, Shinoda N, Juni BA, et al Hib Survey Team. Haemophilus influenzae type b infection, vaccination, and H. influenzae carriage in children in Minnesota, 2008-2009. Epidemiol Infect. 2012;140(3):566-574
32. Recommendations for use of Haemophilus b conjugate vaccines and a combined diphtheria, tetanus, pertussis, and Haemophilus b vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1993;42(RR-13):1-15
33. Haemophilus b conjugate vaccines for prevention of Haemophilus influenzae type b disease among infants and children two months of age and older: recommendations of the ACIP. MMWR Recomm Rep. 1991;40(RR-1):1-7
34. Heath PT. Haemophilus influenzae type b conjugate vaccines: a review of efficacy data. Pediatr Infect Dis J. 1998;17(suppl 9):S117-S122
35. Heath PT, Booy R, Azzopardi HJ, et al. Antibody concentration and clinical protection after Hib conjugate vaccination in the United Kingdom. JAMA. 2000;284(18):2334-2340
36. Ladhani S, Borrow R, Heath PT, Ramsay ME, Booy R. Low serum serotype-specific pneumococcal antibody concentrations in young children with Haemophilus influenzae serotype b (Hib) vaccine failure. Vaccine. 2010;28(28):4440-4444
37. Ladhani S, Heath PT, Slack MP, et al Participants of the European Union Invasive Bacterial Infections Surveillance Network. Haemophilus influenzae serotype b conjugate vaccine failure in twelve countries with established national childhood immunization programmes. Clin Microbiol Infect. 2010;16(7):948-954
38. Santosham M. Can Haemophilus influenzae type b disease be eliminated from the United States? J Pediatr. 2000;137(3):295-298
39. Healthy People 2020 topics and objectives. Available at: www.healthypeople.gov/2020/topicsobjectives2020/default.aspx. Accessed December 5, 2011
40. Dolan JM, Satterfield DA, Hatcher CP, et al. Real-time PCR assays for the detection of H. influenzae serotypes a, b, and f and sequencing of the capsule biosynthesis operons of serotypes c, d, and e. In: Proceedings of the 110th Annual American Society for Microbiology; May 23-May 27, 2010; San Diego, CA